Issue 112, 2015

Targeted delivery of a novel peptide–docetaxel conjugate to MCF-7 cells through neuropilin-1 receptor: reduced toxicity and enhanced efficacy of docetaxel

Abstract

We have designed a novel peptide–docetaxel conjugate, which delivers docetaxel specifically to cancer cell targeting neuropilin-1 (NRP-1) receptor, thus enhancing its efficacy and acts more aggressively in breast cancer cells.

Graphical abstract: Targeted delivery of a novel peptide–docetaxel conjugate to MCF-7 cells through neuropilin-1 receptor: reduced toxicity and enhanced efficacy of docetaxel

Supplementary files

Article information

Article type
Communication
Submitted
19 Aug 2015
Accepted
22 Oct 2015
First published
22 Oct 2015

RSC Adv., 2015,5, 92596-92601

Targeted delivery of a novel peptide–docetaxel conjugate to MCF-7 cells through neuropilin-1 receptor: reduced toxicity and enhanced efficacy of docetaxel

A. Saha, S. Mohapatra, P. Kurkute, B. Jana, J. Sarkar, P. Mondal and S. Ghosh, RSC Adv., 2015, 5, 92596 DOI: 10.1039/C5RA16741H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements